Last reviewed · How we verify

HS-25 and Atorvastatin — Competitive Intelligence Brief

HS-25 and Atorvastatin (HS-25 and Atorvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

phase 3 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

HS-25 and Atorvastatin (HS-25 and Atorvastatin) — Zhejiang Hisun Pharmaceutical Co. Ltd.. HS-25 is a combination therapy where HS-25 (an investigational agent) is co-administered with atorvastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HS-25 and Atorvastatin TARGET HS-25 and Atorvastatin Zhejiang Hisun Pharmaceutical Co. Ltd. phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HS-25 and Atorvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/hs-25-and-atorvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: